URGENT UPDATE: Angelini Pharma has just announced the signing of an exclusive global option agreement with Sovargen for the development and commercialization of a groundbreaking brain health compound, SVG105. This significant deal, revealed today, positions Angelini Pharma at the forefront of brain health innovation as it seeks to tackle pressing neurological disorders.
Under the terms of the agreement, Angelini Pharma will lead the pre-clinical development of SVG105, with the option to advance to clinical development outside of the Republic of Korea, China, Hong Kong, Macau, and Taiwan. This strategic move highlights the company’s commitment to expanding its portfolio in brain health, following a series of recent partnerships.
SVG105, an investigational anti-sense oligonucleotide, targets the mTOR pathways, which are crucial for addressing various brain health disorders, including drug-resistant childhood epilepsy. The agreement includes an upfront payment to Sovargen and potential milestone payments totaling up to approximately $550 million, along with tiered royalties on future sales.
“This partnership with Sovargen solidifies our leading role in brain health,” stated Jacopo Andreose, CEO of Angelini Pharma. “Neurological disorders like epilepsy pose major global health challenges. Our work on SVG105 aims to provide much-needed solutions for those affected by brain health conditions worldwide.”
The need for effective treatments in the brain health sector is urgent. Currently, an estimated 50 million people globally live with epilepsy, with many unable to achieve seizure control despite multiple treatments. SVG105 represents a potential breakthrough in this field, promising new hope for patients struggling with such conditions.
Sovargen’s CEO, Cheolwon Park, expressed enthusiasm about the collaboration, stating, “Our research shows great potential for SVG105 to transform the treatment landscape in brain health. We are confident that Angelini Pharma’s expertise will help advance our mission.”
This agreement comes after Angelini Pharma has made significant strides in brain health over the past two years, including partnerships aimed at developing treatments for rare genetic epilepsies and other neurological disorders. The company’s pipeline now boasts a range of innovative therapies, from small molecules to biologics, demonstrating a robust approach to addressing complex brain health issues.
As the partnership unfolds, the global healthcare community will be closely watching the progress of SVG105. With an urgent need for advanced therapies in neurological disorders, this collaboration could have profound implications for patients and healthcare systems worldwide.
Stay tuned for more updates on this developing story as Angelini Pharma and Sovargen work together to bring new solutions to the brain health landscape.
